Grown Rogue International Past Earnings Performance
Past criteria checks 5/6
Grown Rogue International has been growing earnings at an average annual rate of 68%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually. Revenues have been growing at an average rate of 43.3% per year. Grown Rogue International's return on equity is 30.3%, and it has net margins of 17.7%.
Key information
68.0%
Earnings growth rate
-216.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 43.3% |
| Return on equity | 30.3% |
| Net Margin | 17.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Investors Interested In Grown Rogue International Inc.'s (CSE:GRIN) Revenues
Oct 26
Why We're Not Concerned About Grown Rogue International Inc.'s (CSE:GRIN) Share Price
Jul 01Here's Why Grown Rogue International (CSE:GRIN) Has Caught The Eye Of Investors
Feb 22What Grown Rogue International Inc.'s (CSE:GRIN) P/E Is Not Telling You
Jan 24We Think Grown Rogue International (CSE:GRIN) Is Taking Some Risk With Its Debt
Oct 31Grown Rogue International's (CSE:GRIN) Earnings Offer More Than Meets The Eye
Oct 05Do Grown Rogue International's (CSE:GRIN) Earnings Warrant Your Attention?
Aug 31Grown Rogue International (CSE:GRIN) Has A Somewhat Strained Balance Sheet
Sep 17Does Grown Rogue International (CSE:GRIN) Have A Healthy Balance Sheet?
Jun 01Here's Why Grown Rogue International (CSE:GRIN) Has A Meaningful Debt Burden
Nov 10President J. Strickler Just Bought 5.4% More Shares In Grown Rogue International Inc. (CSE:GRIN)
Feb 11Revenue & Expenses Breakdown
How Grown Rogue International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 22 | 4 | 9 | 0 |
| 31 Oct 23 | 23 | -1 | 7 | 0 |
| 31 Jul 23 | 22 | 1 | 6 | 0 |
| 30 Apr 23 | 20 | 1 | 6 | 0 |
| 31 Jan 23 | 19 | 2 | 6 | 0 |
| 31 Oct 22 | 18 | 0 | 6 | 0 |
| 31 Jul 22 | 16 | 1 | 6 | 0 |
| 30 Apr 22 | 15 | 1 | 6 | 0 |
| 31 Jan 22 | 12 | -2 | 5 | 0 |
| 31 Oct 21 | 9 | -2 | 4 | 0 |
| 31 Jul 21 | 7 | -2 | 3 | 0 |
| 30 Apr 21 | 5 | -3 | 3 | 0 |
| 31 Jan 21 | 4 | -3 | 3 | 0 |
| 31 Oct 20 | 4 | -2 | 3 | 0 |
| 31 Jul 20 | 4 | -4 | 3 | 0 |
| 30 Apr 20 | 3 | -4 | 4 | 0 |
| 31 Jan 20 | 4 | -5 | 4 | 0 |
| 31 Oct 19 | 4 | -9 | 5 | 0 |
| 31 Jul 19 | 4 | -10 | 5 | 0 |
| 30 Apr 19 | 4 | -10 | 4 | 0 |
| 31 Jan 19 | 3 | -11 | 4 | 0 |
| 31 Oct 18 | 2 | -8 | 4 | 0 |
| 31 Jul 18 | 1 | -5 | 4 | 0 |
| 31 Oct 17 | 0 | 0 | 1 | 0 |
Quality Earnings: GRIN has a high level of non-cash earnings.
Growing Profit Margin: GRIN's current net profit margins (17.7%) are higher than last year (7.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GRIN has become profitable over the past 5 years, growing earnings by 68% per year.
Accelerating Growth: GRIN's earnings growth over the past year (188.5%) exceeds its 5-year average (68% per year).
Earnings vs Industry: GRIN earnings growth over the past year (188.5%) exceeded the Pharmaceuticals industry -51.1%.
Return on Equity
High ROE: GRIN's Return on Equity (30.3%) is considered high.